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Objectives: Combination antiretroviral therapy (cART) is associated with increased survival 
among HIV-infected persons. Yet, no research to date has examined whether introduction of 
once-daily fixed-dosed combinations (FDC) affects the likelihood of cART initiation. We aimed 
to determine whether implementation of once-daily FDC regimens was associated with changes 
to cART initiation. We also identified clinical, treatment regimen, and provider characteristics 
possibly associated with cART initiation.
Study design: Retrospective observational analysis.
Methods: We queried electronic medical records between July 1999–June 2006 to identify 
incident cases of detectable HIV infection in antiretroviral-naïve adults. Cox regression with 
time-dependent covariates was used to examine the effects of once-daily FDC era, clinical, 
provider, and treatment regimen characteristics on cART initiation.
Results: Once-daily FDC availability did not change the likelihood of cART initiation, but other 
characteristics were associated with an increased likelihood: AIDS diagnosis, above-median 
daily pill consumption, and 16+ yrs of physician HIV experience. Decreased likelihood of cART 
initiation was associated with CD4 201–350 cells/µL, HIV RNA  100,000 copies/mL, and 
with CD4  350 cells/µL (any HIV RNA level), compared to CD4  200 cells/µL.
Conclusion: Availability of once-daily FDC-based regimens did not affect likelihood of 
cART initiation. Patient clinical characteristics appear to be more important predictors of 
cART initiation.
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Introduction
In the 1990s, when combination antiretroviral therapy (cART) was developed, 
treatment regimens involved multiple pills, dosages, and potentially complex drug-drug 
interactions.1,2 However, these regimens were also successful, so simplifying them was a 
priority.3,4 Since 2005, physicians have been able to prescribe combination antiretroviral 
(ARV) regimens as simple as one pill daily, and patient-level data indicate preference for 
these easier-to-follow regimens.5,6 What is not clearly understood, however, is whether 
regimen simplification is independently associated with initiation of cART, irrespective 
of clinical factors such as CD4 count and human immunodeficiency virus (HIV) RNA 
levels identified in HIV treatment guidelines.7,8 Such research is important to better 
understand whether adoption of new treatment regimens may unduly affect clinician pre-
scribing practices, independent of predictors identified in HIV treatment guidelines.
Early studies by Kitahata9 indicated that more experienced HIV providers were 
more likely to initiate cART earlier, and to follow established HIV care guidelines. HIV/AIDS - Research and Palliative Care 2010:2 20
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By late 1990s, HIV care guidelines advocated a “hit early, 
hit hard” philosophy.1,2 However, as research came to light 
that ARV therapy could eventually produce accumulated 
adverse effects, HIV care providers became more reluctant 
to initiate ARV therapy when CD4 T-cell counts were greater 
than 350 cells/µL, with many preferring to wait until the 
patient’s CD4 count dropped to 200 cells/µL.10 HIV care 
guidelines from the early 2000s reflected this reluctance.3,4 
Now that once-daily fixed-dose combination (FDC) therapies 
are available, as are therapies with fewer adverse effects, 
many researchers are suggesting that a more aggressive 
approach to ARV-naïve patients is in order, particularly in 
light of studies showing better long-term outcomes with 
earlier initiation of therapy.11–14
Clearly, research is lacking on how recent developments 
in ARV therapy, especially FDC therapies and fewer dosages 
daily, have affected HIV care providers’ prescribing habits 
in regards to cART initiation. Therefore, our study on cART 
initiation among ARV-naïve (never exposed to ARV medi-
cations) HIV-infected patients had two primary objectives: 
1) to determine whether initiation of cART changed before 
and after the introduction of once-daily FDC therapies into 
clinical practice; and, 2) to identify patient clinical charac-
teristics, provider characteristics, and/or treatment regimen 
characteristics associated with cART initiation after adjusting 
for implementation of once-daily FDC therapies into clinical 
practice. Kaiser Permanente (KP), a multi-state integrated 
healthcare system, is ideally suited to study such potential 
prescribing changes over time.
Methods
Study population
We queried the electronic medical record (EMR) databases 
of three KP regions: Northern California, Northwest (ie, met-
ropolitan Portland, Oregon), and Georgia (ie, metropolitan 
Atlanta) to identify adult HIV-infected ARV-naïve patients 
(males and females aged 18 years old). KP is an integrated 
health care system serving over eight million individuals in 
the United States. Together, these three regions represent 
45%–50% of KP’s HIV population.
The study observation period was from July 1st, 1999 
through June 30th, 2006. An ARV-naïve patient was defined 
by the following inclusion and exclusion criteria:
1.  Laboratory results showing detectable HIV RNA (defined 
as 75 copies/mL of HIV RNA) on a report generated 
between July 1st, 1999 through June 30th, 2006 (the index 
date), but not before July 1st, 1999 (ie, new treatment 
candidates).
2.  One hundred eighty three or more days of KP health plan 
coverage (including KP pharmacy benefits) prior to the 
index date (the start date, earliest was January 1st, 1999; 
latest was December 31st, 2005).
3.  One hundred eighty three or more days of KP health plan 
coverage (including KP pharmacy benefits) after the index 
date.
4.  ARV-naïve: no history of ARV treatment in the 183 days 
prior to the index date.
All patients were followed for a minimum of 183 days 
after the index date until the earliest of the following: 
1) initiation of first cART regimen (event date, our primary 
outcome); 2) death; 3) end of observation period (December 
31st, 2006); or 4) start of first health plan disenrollment last-
ing four or more months. The date associated with any such 
event was the exit date. If cART recipients received one or 
more cART regimens during the follow-up period, only the 
first regimen was counted as an event. Cohort members who 
never received a cART regimen during the follow-up period 
(through December 31st, 2006) had a censored outcome at 
their exit date.
Data sources and measures
Data sources
Appropriate pharmacy, laboratory, utilization, membership 
eligibility, and provider employment databases in each 
respective KP region were queried to obtain outcome and 
predictor data elements between January 1st, 1999 and 
December 31st, 2006. We searched records for diagnostic 
or treatment evidence of four co-morbidities dating back 
to 1995: coronary artery disease (CAD), diabetes mellitus 
(DM), active hepatitis B (HBV), and hepatitis C (HCV).
Outcome measure
The primary outcome measure was time to event of first 
pharmacy dispensing of cART after the index date. cART was 
defined as 3 ARVs that met one of the acceptable combina-
tions, based on 2006 DHHS treatment guidelines.15
Primary independent variable
The once-daily FDC time era was the primary independent 
variable in this study, and was treated as a time-dependent 
indicator (pre- vs post-FDC eras). The pre-FDC era included 
dates between July 1st, 1999 and December 31st, 2004, 
while the post-FDC era was defined as January 1st, 2005 
through June 30th, 2006. We selected January 1st, 2005 as 
the start date of the post-FDC era, because once-daily FDC 
treatment regimens were implemented within KP from this HIV/AIDS - Research and Palliative Care 2010:2 21
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date (January 1st, 2005) forward. Patients who contributed 
information in both eras were represented by at least two 
records in the time-dependent dataset. Although twice-daily 
FDC treatment regimens were used in clinical practice begin-
ning in 1998 within KP, we focused on the once-daily FDC 
treatment period (starting in January 1st, 2005) because of 
the potentially larger impact on cART initiation.
Secondary independent variables
Secondary independent variables included clinical, provider, 
and treatment-regimen characteristics. Clinical variables 
collected were: 1) CD4 T-cell count; 2) HIV RNA level; 
3) an indicator (yes/no) of whether patient met criteria for 
AIDS diagnosis (1993 CDC Classification); 4) an indicator 
of CAD or DM diagnosis; and 5) an indicator of HCV and/
or HBV diagnosis. Values for each measure were assessed 
as close as possible to the index date and then updated 
throughout the study period as clinical values changed. 
A CD4 T-cell count/HIV RNA composite measure was 
defined using 6 levels: 1) CD4  200 cells/µL and HIV 
RNA  100,000 copies/mL; 2) CD4  200 cells/µL and HIV 
RNA  100,000 copies/mL; 3) CD4 201–350 cells/µL and 
HIV RNA  100,000 copies/mL; 4) CD4 201–350 cells/µL 
and HIV RNA  100,000 copies/mL; 5) CD4  350 cells/µL 
and HIV RNA  100,000 copies/mL; and 6) CD4  350 cells/
uL and HIV RNA  100,000 copies/mL. This six-level 
classification measure was based on previous cutpoints 
established in the HIV literature that examined CD4 and 
HIV RNA levels associated with mortality.3,16
Provider characteristics were: 1) years caring for HIV 
patients within the KP system; 2) HIV panel size per clini-
cian; and 3) medical specialty (HIV specialist with infectious 
disease certification, HIV specialist, noninfectious disease 
certification, or general medicine). This information was col-
lected as close as possible to index date and updated annually 
throughout the follow-up period, if a provider characteristic 
had changed, or if a patient changed provider in the previ-
ous year. We collapsed years spent caring for HIV patients 
into a four-level ordinal variable (0–5 years, 6–11 years, 
12–16 years, 16 years), and did the same with HIV panel 
size (50, 51–100, 101–200, 201+).
Treatment regimen characteristics included: 1) patient 
average daily total pill count, and 2) region-wide median 
daily ARV pill count. These counts represent patient bur-
den of overall pill-taking between the start and exit date 
(not time-dependent), as well as the burden of HIV treatment 
for all patients, at the same period in the same region as a 
given patient, respectively.
Average daily pill count for a patient was calculated 
as the sum of all prescriptions (pills per day multiplied by 
the number of days’ supply) divided by the number of days 
between the start and exit dates. For example, the average 
daily pill count for a patient with 365 days of follow-up time 
that had 18 total dispensings, with each dispensing taken 
twice per day for a total of 30 days (days’ supply) would be 
as follows: 18 × [(2 × 30)]/365 = 2.96 pills per day. Only 
oral pill-based medications were included. For analysis, the 
measure is dichotomized at the median overall patients in 
the analysis sample.
Aggregate, region-based ARV pill count is defined as 
the median daily count of cART pills dispensed among all 
HIV+ patients in that patient's region (ie, not restricted to 
patients included in this study), upon the first dispensing 
that met cART criteria. Rather than a patient-based aver-
age of all medications between the start and exit date, 
the region-based pill-count measure assessed the median 
daily pill count of ARV medications upon the first cART 
dispensing among all patients within the study region that 
qualified for cART. To more precisely measure changes in 
regional cART dispensing practices over time, the measure 
was updated every six months (January 1st–June 30th, 
July 1st–December 31st) between a patient’s start-to-exit 
dates, so this variable was time-dependent. For example, if 
a patient had an index date of March 15th, 2001, the region-
based ARV pill count for that patient would be the value 
for the patient's region for January 1st–June 30th, 2001. 
Because this measure was region-, rather than patient-based, 
patients with index dates between January 1st–June 30th 
or July 1st–Dec 31st would have identical region-based 
ARV pill count values. For analysis, the region-based ARV 
pill-count measure was also dichotomized at the median 
(calculated over all regions).
Control variables
Five background variables served as control variables: 
1) age at index date; 2) sex; 3) race/ethnicity (white, African 
American, Hispanic, Asian-American, other/unknown); 
4) an indicator of injection drug use (IDU) status (yes vs no/
unknown); and 5) KP region location (Northern California, 
Northwest, Georgia).
Analysis
Cox proportional-hazards regression with time-dependent 
covariates was used to estimate the relative hazard of cART 
initiation as a function of risk profile, where risk profile 
was defined as a combination of provider, clinical, and HIV/AIDS - Research and Palliative Care 2010:2 22
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A total of 2,127 patients met initial inclusion criteria. Of these, 
1,662 (78.1%) had an index date in the pre-FDC era, while 465 
(21.9%) had an index date in the post-FDC era (Tables 1, 2).
Demographic characteristics
Nearly 90% of patients were male, with a mean age close to 
40 years (Table 1). About half of these patients were non-
Caucasian. Mirroring the national KP population, more than 
two-thirds of patients were identified from the (Northern) Cali-
fornia region. Fewer than 6% had records indicating history of 
injection drug use as an HIV risk behavior. The distribution 
of race/ethnicity appears to be significantly different across 
the two FDC-time eras, primarily due to an increase in other/
unknown category. No other demographic differences were 
noted between the pre- and post-once-daily FDC eras.
Clinical characteristics
As of index date, nearly 40% of the population had CD4 
 200 cells/µL, while about one-third had CD4  350 cells/µL 
and HIV RNA  100,000 copies/mL (Table 2). About 34% 
met AIDS criteria. Fewer than 5% had documentation of active 
treatment regimen characteristics. To check whether the 
proportional hazards assumption was violated, we estimated 
the Kaplan–Meier survival density function (SDF) for each 
independent variable, as well as the plot of log time vs log 
negative log of the SDF. If curves crossed or were overlaid, 
we made adjustments to the category definition for that vari-
able. To reduce proportional hazards violation, HIV panel size 
was dichotomized (0–100, 101+). We found that CAD/DM 
could be eliminated because the SDF for positive and negative 
values was the same. Finally, the number of categories for the 
CD4 T-cell count/HIV RNA composite could be reduced to 
five by combining the two CD4  200 cells/µL categories, 
which had the same SDF.
Last, we used Cochran–Mantel–Haenszel tests of general 
association to check for collinearity between pairs of inde-
pendent variables. Because we found that provider specialty 
was strongly associated with panel size (P  0.0001), as well 
as violated the proportional hazards assumption, we dropped 
it from the variable list.
We obtained approval from all regional KP Institutional 
Review Boards. The Institutional Review Boards waived 
the requirement for informed consent prior to the start of the 
study for all patients.
Table 1 Descriptive analysis: patient demographic characteristics
Demographics Overall  
N = 2,127
Pre-FDC era1  
N = 1,662
Post-FDC era2  
N = 465
P* 
Age (mean ± SD) 41.1 ± 9.8 41.0 ± 9.7 41.2 ± 10.4 nS**
Male: n (%) 1,876 (88.2) 1,451 (87.3) 425 (91.4) nS**
Race/ethnicity: n (%)3 0.0001
  White 996 (46.8) 780 (46.9) 216 (46.5)
  African American 518 (24.4) 423 (25.5) 95 (20.4)
  Hispanic 271 (12.7) 226 (13.6) 45 (9.7)
  Asian American 93 (4.4) 68 (4.1) 25 (5.4)
  Other/Unknown 249 (11.7) 165 (9.9) 84 (18.1)
IDU risk category: n (%)3 nS**
  Yes 121 (5.7) 97 (5.8) 24 (5.2)
  no 1,046 (49.2) 827 (49.8) 219 (47.1)
  Information not available 960 (45.1) 738 (44.4) 222 (47.7)
KP region location: n (%)3 nS**
  georgia 409 (19.2) 313 (18.8) 96 (20.7)
  northern California 1,546 (72.7) 1,212 (72.9) 334 (71.8)
  northwest 172 (8.1) 137 (8.2) 35 (7.5)
*Test that baseline characteristics differed between pre-FDC and post-FDC eras, 2-tailed alpha = 0.05.
**“NS” (not significant), defined as P  0.05.
1Includes index dates  7/1/1999 and  12/31/2004.
2Includes index dates  1/1/2005 and  6/30/2006.
3Column percentages may not add up to 100% due to rounding.
Abbreviations: FDC, fixed dose combination; IDU, injection drug use; KP, Kaiser Permante.HIV/AIDS - Research and Palliative Care 2010:2 23
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HBV and/or HCV . There were some differences in clinical 
characteristics between the two FDC-time eras. The distribu-
tion of CD4 count/HIV RNA level and of proportion meeting 
AIDS criteria differed significantly between the two FDC time 
eras. No other clinical differences were noted at baseline.
Provider characteristics
As of index date, most patients were assigned to providers with 
the following characteristics: 12 or more years of HIV experience 
(55.3%) and HIV panel sizes greater than 100 (57.0%) (Table 2). 
The distributions of years of HIV experience were significantly 
different between the two FDC-time eras; however, no differ-
ences were reported for HIV panel size.
Treatment regimen characteristics
The patient-based median total pill count was 1.7 pills per 
day overall, dropping from 1.8 pills per day in the pre-FDC 
era to 1.3 pills per day in the post-FDC era (Table 2). 
The region-based median ARV pill count (upon first cART 
dispensing for all HIV patients) was 13.0 pills per day 
overall, dropping from 18.0 pills per day in the pre-FDC era 
to 6.0 pills per day in the post-FDC era.
Table 2 Descriptive analysis: baseline clinical, provider, and treatment regimen characteristics
Characteristic Overall  
N = 2,127
Pre-FDC era1  
N = 1,662




CD4 (#/µL) and HIV RnA level (copies/mL):
n, (%)3,4
0.0001
  CD4  200 786 (37.0) 653 (39.3) 133 (28.6)
  CD4 201–350 and HIV RnA  100 K 396 (18.6) 313 (18.8) 82 (17.6)
  CD4 201–350 and HIV RnA  100 K 111 (5.2) 83 (5.0) 28 (6.0)
  CD4  350 and HIV RnA  100 K 737 (34.7) 537 (32.3) 200 (43.0)
  CD4  350 and HIV RnA  100 K 98 (4.6) 76 (4.6) 22 (4.7)
AIDS criteria; n (%)5 731 (34.4) 591 (35.6) 140 (30.1) 0.05
Active HBV and/or HCV; n (%)5 91 (4.3) 75 (4.5) 16 (3.4) nS**
Provider
Years caring for HIV patients: n (%)3,6 0.0001
  0–5 392 (18.4) 254 (15.3) 158 (29.7)
  6–11 527 (24.8) 451 (27.1) 76 (16.3)
  12–16 793 (37.3) 704 (42.4) 89 (19.1)
  16 383 (18.0) 227 (13.7) 156 (33.6)
  Information not available 32 (1.5) 26 (1.6) 6 (1.3)
HIV panel size: n (%)3,6 nS**
  100 882 (41.5) 685 (41.2) 197 (42.4)
  101+ 1213 (57.0) 951(57.2) 262 (56.3)
  Information not available 32 (1.5) 26 (1.6) 6 (1.3)
Treatment regimen
Total pill count per day (median, IQR)7 1.7, 0.6–3.2 1.8, 0.7–3.4 1.3, 0.4–2.8 0.01
Region-based ARV pill count per day (median, IQR)8 13.0, 6.0–22.0 18.0, 11.0–22.0 6.0, 6.0–7.0 0.0001
*Test that baseline characteristics differed between pre-FDC and post-FDC eras, 2-tailed alpha = 0.05.
**“NS” (not significant) defined as P  0.05.
1Includes index dates  7/1/1999 and  12/31/2004.
2Includes index dates  1/1/2005 and  6/30/2006.
3Column percentages may not add up to 100% due to rounding.
4Baseline lab values (CD4, HIV RnA) include valid test closest to index date.
5Baseline disease assessments include AnY presence of disease (yes/no) between start date and index date.
6Baseline provider variables calculated as of calendar year of index date.
7Total pill count per day calculated from start date through exit date. Formula = Sum (pills per day [both ARV and non ARV] × day supply)/exit date - start date.
8Region-based aggregate ARV pill count calculated as of six-month time period of index date. Includes count of total pills per day/per patient upon first dispensing that meets 
cART regimen among all HIV patients within each region.
Abbreviations: FDC, fixed dose combinationl IQR, interquartile range; HBV, hepatitis B; HCV, hepatitis C.HIV/AIDS - Research and Palliative Care 2010:2 24
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Table 3 Association of FDC treatment era status, clinical, provider, and treatment regimen characteristics with initiation of cART 
(n = 2,069)1
Characteristic Hazard ratio 95% CI
FDC time era
  Pre period (Ref. group) 1.00 nA
  Post period 0.92 0.79–1.08
Clinical
CD4 (#/µL) and HIV RnA Level (copies/mL)
  CD4  200 1.00 nA
  CD4 201–350 and HIV RnA  100 K 1.24 0.95–1.62
  CD4 201–350 and HIV RnA  100 K 0.76 0.62–0.94
  CD4  350 and HIV RnA  100 K 0.69 0.51–0.93
  CD4  350 and HIV RnA  100 K 0.15 0.12–0.20
No AIDS-defining illness (Ref. group) 1.00 nA
AIDS-defining illness 2.05 1.68–2.50
no active HCV and/or HBV (Ref. group) 1.00 nA
Active HCV and/or HBV 0.97 0.78–1.19
Provider
Years caring for HIV patients
  0–5 (Ref. group) 1.00 nA
  6–11 1.08 0.92–1.26
  12–16 1.09 0.95–1.25
  16 1.31 1.02–1.68
HIV panel size
  100 (Ref. group) 1.00 nA
  101+ 1.01 0.90–1.13
Treatment regimen
Total pill count per day (Patient-based)
  Median (Ref. group) 1.00 nA
  Median 1.56 1.38–1.77
ARV pill count per day (Region-based)
  Combined region median (Ref. group) 1.00 nA
  Combined region median 1.15 0.94–1.40
1The effective sample size for the Cox regression (because of missing data) was 2,069. Models adjusted for age (median = ref. group vs median), gender (female = ref. 
group vs male), race/ethnicity (white = ref. group vs non-white ethnicity/other/unknown), IDU risk category (no = ref. group vs yes/unknown), and region (non-California 
regions = ref. group vs California region).
Abbreviations: ARV, antiretroviral; HCV, hepatitis C; HBV, hepatitis B.
Results of the Cox regression analysis
A total of 2,069 of the 2,127 patients (97.3%), representing 
1,272 events, had complete information available for 
multivariate analysis (Table 3).
FDC treatment era
The introduction of once-daily, fixed-dose combination 
therapies (FDC era) was not significantly associated 
(hazard ratio [HR] = 0.92, 95% confidence interval [CI]: 
0.79–1.08) with initiation of cART, after adjusting for 
clinical, provider, treatment regimen, and demographic 
characteristics.
Clinical characteristics
Clinical characteristics were the strongest predictors of 
cART initiation. Compared to CD4  200 cells/µL (refer-
ence category), the following characteristics were associated 
with a decreased likelihood of cART initiation: 1) CD4 
201–350 cells/µL and HIV RNA  100,000 (HR = 0.76, 
95% CI: 0.62–0.94), 2) CD4  350 cells/µL and HIV RNA HIV/AIDS - Research and Palliative Care 2010:2 25
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 100,000 copies/mL (HR = 0.69, 95% CI: 0.51–0.93), and 
3) CD4  350 cells/µL and HIV RNA  100,000 copies/mL 
(HR = 0.15, 95% CI: 0.12–0.20). Patients who met AIDS 
criteria were more likely to receive cART (HR = 2.05, 95% 
CI: 1.68–2.50), compared to patients who did not meet 
AIDS criteria.
Provider characteristics
Compared to patients assigned to providers with 0–5 years 
of experience caring for HIV patients in the KP system, 
patients assigned to providers with 16 years of experi-
ence were more likely to initiate cART (HR = 1.31, 95% 
CI: 1.02–1.68). HIV panel size was not significantly associ-
ated with likelihood of cART initiation.
Treatment regimen characteristics
Patients with total pill count per day above the group 
median were more likely to initiate cART (HR = 1.56, 95% 
CI: 1.38–1.77), compared to patients with total pill count per 
day below the group median. Aggregate, region-based ARV 
pill count upon first cART dispensing was not significantly 
associated with likelihood of cART initiation.
Discussion
We found that implementation of once-daily FDC treatment 
regimens into clinical practice did not significantly affect 
initiation of cART. The finding that implementation of 
once-daily FDC treatment regimens was not independently 
associated with cART initiation is significant for HIV care. 
These results are significant because of potential concerns 
that the implementation of new drug combinations, while 
offering many patient advantages, may unduly influence 
provider prescribing behavior, independent of important 
clinical characteristics. Our findings showed this not the case. 
Rather, we found that KP clinicians’ prescribing practices 
were independent of new drug combinations. Consistent 
with treatment guidelines, clinical factors such as CD4 T-cell 
count, HIV/RNA levels, and AIDS criteria were the strongest 
predictors of cART initiation. This is the first study we know 
of to examine the independent effect of implementation of 
once-daily FDC treatment regimens on initiation of cART.
Of particular interest from a health-care delivery perspec-
tive, we found that providers with 16+ years of experience 
caring for HIV patients were more likely to initiate cART, 
compared to providers with 0–5 years of experience. These 
results confirm other research findings9 demonstrating ben-
efits to HIV patients who have more experienced providers. 
This study finding has important implications for policy and 
practice. Our results suggest that within KP, ARV-naïve HIV 
patients assigned to providers with longer experience treating 
HIV patients may benefit from more appropriate pharmaco-
therapy such as earlier cART initiation.
We also found that higher total pill count per day was 
associated with initiation of cART. This may be because 
higher pill counts are potentially related to more advanced 
disease stage, disease burden, and/or co-morbidities, which 
may cause clinicians to be more aggressive in treatment, 
as there is some evidence that greater HIV viral control 
leads to improved health generally. Indeed, in the overall 
study population, 56% of patients either had a CD4 T-cell 
count 200 cells/µL (37%), or CD4 T-cell count 201 
to 350 cells/µL with HIV-1 RNA  100,000 copies/mL 
(Table 2), indicating a substantial proportion of individu-
als with more advanced disease and/or a more compelling 
need to initiate therapy, as per treatment guidelines.2,3,15 In 
contrast, however, higher overall pill count was associated 
with cART initiation, even after adjusting for CD4 T-cell 
count and HIV-1 RNA levels, the primary surrogate markers 
for assessing disease stage. Thus, more research is needed to 
fully interpret the association of total overall pill count per 
day with initiation of cART.
This study had several limitations. First, we could not 
capture physician orders to place patients on cART rather 
than pharmacy dispensings for cART. Measuring physician 
orders for cART would likely be a more sensitive method of 
detecting changes in initiation of cART after implementa-
tion of the once-daily FDC treatment era. Second, we were 
not able to measure years of provider experience caring for 
HIV patients prior to employment with KP. In addition, the 
finding that years of provider experience was associated with 
cART initiation cannot be generalized beyond KP. Third, 
limited follow-up time in the once-daily post-FDC era (about 
1.5 years vs 5.5 years in the pre-FDC era) reduced our ability 
to detect differences in cART initiation in the post-FDC era. 
Fourth, we had few measures of patient-level socioeconomic 
status, such as educational level and income, available for 
analysis. Last, our study results may not be generalizable to 
nongroup-model HMO settings.
Our study showed that CD4 T-cell count, HIV RNA levels 
and meeting AIDS criteria were the strongest predictors of 
cART initiation. This result is very encouraging because it 
indicates that new, more convenient drug combinations do not 
necessarily unduly influence provider prescribing behaviors, 
independent of patient and clinical characteristics. Future 
research is needed to understand the effect of initiation of the 
once-daily FDC treatment era on patient outcomes among HIV/AIDS - Research and Palliative Care 2010:2
HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open-access journal focusing on advances in research in 
HIV, its clinical progression and management options including anti-
viral treatment, palliative care and public healthcare policies to control 
viral spread. The journal welcomes original research, basic science, 
clinical & epidemiological studies, reviews & evaluations, expert 
opinion & commentary, case reports & extended reports. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
26
Mosen et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
an HIV-infected ARV-naïve population. Specifically, more 
research is needed to understand whether the advent of the once-
daily FDC treatment era affected patient treatment-adherence 
levels, quality-of-life outcomes, and morbidity and mortality.
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